EBITDA Margin % is calculated as EBITDA divided by its Revenue. New Horizon Health's EBITDA for the
six
months ended in Jun. 2023 was HK$19 Mil. New Horizon Health's Revenue for the
six
months ended in Jun. 2023 was HK$900 Mil. Therefore, New Horizon Health's EBITDA margin for the quarter that ended in Jun. 2023 was 2.15%.
New Horizon Health (HKSE:06606) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
New Horizon Health EBITDA Margin % Related Terms
New Horizon Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for New Horizon Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06606 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, New Horizon Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where New Horizon Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (HKSE:06606) has a EBITDA Margin % of 2.15% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on New Horizon Health and its competitors.
Is New Horizon Health's EBITDA Margin % too high?
New Horizon Health's current EBITDA Margin % is 2.15%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. New Horizon Health's value of 2.15% is 71.2% below this industry median. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's EBITDA Margin % compare to ABT and SYK?
New Horizon Health's EBITDA Margin % of 2.15% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.47. New Horizon Health's value of 2.15% is 71.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Horizon Health's current EBITDA Margin % of 2.15% is 71.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on New Horizon Health and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Horizon Health's current EBITDA Margin % is 2.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (HKSE:06606) has a current EBITDA Margin % of 2.15%. The current EBITDA Margin % is 2.15% and 71.2% below the Medical Devices & Instruments industry median of 7.47. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For New Horizon Health (HKSE:06606), the current EBITDA Margin % is 2.15% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score
Get the complete analysis for HKSE:06606
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06606 has been successfully added to your 
